Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Relapsed/Refractory Multiple Myeloma
NCT00017433Phase 2Terminated
- Sponsor
- CTI BioPharma Corp.
- Start
- Jan 2001
- Primary completion
- Jan 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of arsenic trioxide in multiple myeloma (MM), sponsored by CTI BioPharma Corp.. Started Jan 2001; status: terminated.
02
Drugs
arsenic trioxide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00017433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017433.